CGTX: the cashflow

MyFinsight

For the quarter ending 2025-09-30, CGTX had $28,266K increase in cash & cash equivalents over the period.

Unit: Thousand (K) dollars (except for numbers of shares and EPS)

Cash Flow	2025-09-30	2025-06-30
Grant income	1,215	-
Clinical programs	1,435	-
R&d personnel costs	1,248	-
Preclinical programs	37	-
Manufacturing	751	-
Other research and development expenses	-5	-
General and administrative expenses (excluding equity-based compensation)	2,387	-
Equity-based compensation	522	-
Other segment items	-230	-
Net loss	-4,930	-15,214
Depreciation and amortization	15	7
Equity-based compensation	522	1,207
Amortization of right-of-use assets	46	99
Grant receivables	-4,385	3,599
Prepaid expenses and other assets	-47	-653
Accounts payable and accrued expenses	-5,443	539
Deferred grant income and other liabilities	-246	916
Operating lease liabilities	-47	-108
Net cash used in operating activities	-5,651	-15,500
Proceeds from issuance of common stock-Registered Direct Offering	27,940	-
Proceeds from issuance of common stock-At Market Offering	5,989	2,337
Proceeds from the exercise of common stock options	65	-
Payment of employee withholding taxes on vested rsus	36	51
Payments on loan payable	41	238
Net cash provided by financing activities	33,917	2,048
Net increase (decrease) in cash, cash equivalents and restricted cash equivalents	28,266	-13,452
Cash and cash equivalents at beginning of period	25,009	-
Cash and cash equivalents at end of period	39,823	-

Unit: Thousand (K) dollars